31 In a trial evaluating semaglutide for weight loss, the incidence of acute pancreatitis was still low (3 of 1,306 participants) despite a higher dose and more significant weight loss, but none of the 655 individuals in the placebo group developed pancreatitis
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, has emerged as an important therapeutic advancement due to its substantial weight-reduction effects and metabolic benefits
It requires Reconstitution before use
These effects may help: Reduce appetite Increase satiety Support healthier eating habits Improve blood sugar regulation Encourage long-term weight loss Its ability to affect multiple pathways simultaneously is one reason researchers have been excited about its potential role in weight management
GLP-1 receptor agonists mimic natural gut hormones to reduce appetite, slow gastric emptying, and promote gradual weight reduction over 612 months